Alcon Labs Inc patents expiration
1. Eysuvis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857096 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11219596 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10993908 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10940108 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10646436 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10945948 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11596599 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 26, 2023 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 26 October, 2020
Treatment: A method for treating dry eye in a patient; A method for delivering a composition to a mucus membrane; A method for delivering a pharmaceutical agent across a mucosal barrier; Administration to the ey...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
EYSUVIS family patents
2. Inveltys patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646437 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9532955 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9056057 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10864219 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9737491 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US9827191 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US11219597 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US10058511 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US11642317 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| US10688045 | ALCON LABS INC | Compositions and methods for ophthalmic and/or other applications |
May, 2033
(9 years from now) | |
| US9393213 | ALCON LABS INC | Nanocrystals, compositions, and methods that aid particle transport in mucus |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 22, 2021 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 August, 2018
Treatment: A method for delivering a composition to a mucus membrane; A method for treating ocular inflammation; A method for delivering a pharmaceutical agent across a mucosal barrier; A method for treating inf...
Dosage: SUSPENSION/DROPS;OPHTHALMIC
INVELTYS family patents
3. Pataday Once Daily Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5641805 | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Jun, 2015
(8 years ago) | |
|
US5641805 (Pediatric) | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Dec, 2015
(8 years ago) | |
| US7402609 | ALCON LABS INC | Olopatadine formulations for topical administration |
Jun, 2022
(1 year, 10 months ago) | |
|
US7402609 (Pediatric) | ALCON LABS INC | Olopatadine formulations for topical administration |
Dec, 2022
(1 year, 4 months ago) | |
| US6995186 | ALCON LABS INC | Olopatadine formulations for topical administration |
Nov, 2023
(5 months ago) | |
|
US6995186 (Pediatric) | ALCON LABS INC | Olopatadine formulations for topical administration |
May, 2024
(14 days from now) | |
| US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: Method of treating allergic conjunctivitis; Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF family patents
4. Pataday Twice Daily Relief patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5641805 | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Jun, 2015
(8 years ago) | |
|
US5641805 (Pediatric) | ALCON LABS INC | Topical ophthalmic formulations for treating allergic eye diseases |
Dec, 2015
(8 years ago) | |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 December, 1996
Treatment: Treating allergic eye diseases in humans
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY TWICE DAILY RELIEF family patents
5. Rhopressa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
RHOPRESSA family patents
6. Rocklatan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9993470 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11197853 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
| New Combination(NC) | Mar 12, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
ROCKLATAN family patents
7. Simbrinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6316441 | ALCON LABS INC | Brinzolamide and brimonidine for treating glaucoma |
Dec, 2019
(4 years ago) | |
| US9421265 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Jun, 2030
(6 years from now) | |
| US9044484 | ALCON LABS INC | Aqueous pharmaceutical compositions containing borate-polyol complexes |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Apr 19, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE; BRINZOLAMIDE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SUSPENSION/DROPS;OPHTHALMIC
SIMBRINZA family patents